Vasomotor Symptoms Market: By Therapy Type (Hormonal (Estrogen, Progesterone, Combination), Non-Hormonal (Anti-Depressants, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores), Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast to 2027

Vasomotor Symptoms Market Forecast:

Vasomotor Symptoms Market is anticipated to hold a value of USD 5.48 Billion by 2030 and is expected to register a CAGR of 6.90% during the assessment period of 2022 to 2030.

Market Synopsis

The increasing number of menopausal women demand treatment for hot flashes and vaginal dryness. In the US, approximately 1.3 million women become menopausal each year. With such increased statistics, there is a huge demand for treatment options for vasomotor symptoms of menopause. Also, the companies operating in the market are focused on research and development for the production of a therapy that is completely harmless without any side-effects.

Market Influencer

The companies operating in the vasomotor symptoms market are focused on receiving approvals from regulatory authorities to create a competitive edge over the products from their competitors. Also, established players are investing in clinical trials for the differentiation of products. Such initiatives promise an enormous level of growth in the market.

Market Drivers

• Rise in the number of companies investing in clinical trial candidates and research and development acts as a major contributor to the growth of the vasomotor symptoms market. For instance, in January 2020, KaNDy Therapeutics, the UK clinical-stage biotech company, received positive data from its Phase 2b “SWITCH-1” clinical trial with its lead non-hormonal drug candidate, NT-814, for the treatment of vasomotor symptoms of menopause. Similarly, Radius Pharma (US) includes an investigational drug Elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women in its pipeline portfolio.

• Increasing product launches by prominent players in the market. For instance, In April 2019, Otsuka Pharmaceutical launched EQUELLE, a non-prescription, non-hormonal supplement to alleviate the frequency of hot flashes and muscle aches associated with menopause in the US

• Increasing incorporation of innovation in the industry

• High investment in research and development

• Growing awareness created by medical professionals and key players about the benefits of hormonal therapies

Market Restraints

• Side-effects and complications can reduce the preference rate. Hormone therapy is the most effective treatment for menopausal symptoms such as hot flashes and vaginal dryness. Hormone replacement therapy also helps to balance estrogen and progesterone in women around the time of menopause. However, this therapy is known to cause side-effects, such as bleeding, bloating, breast tenderness or enlargement, headaches, mood changes, and nausea.

• The COVID-19 pandemic has caused disruption in the supply chains of the drugs, which can lead to demand and supply gaps for countries dependent on trade affairs for drugs.

Segmentation

By Therapy Type

• Hormonal: The hormonal segment held the majority share in 2019 in the therapy type segment. The hormonal segment has been further segmented into estrogen, progesterone, and combination. The large share of this segment can be attributed to the growing inclination of companies towards this therapy for the treatment and management of vasomotor symptoms. In addition to that, several companies have received approvals from regulatory authorities, which is also leading to an increased market share of estrogen-progesterone therapy. For instance, TherapeuticsMD in 2018, received FDA approval for its first bioidentical hormone therapy BIJUVA, a combination of estradiol and progesterone for moderate to severe vasomotor symptoms associated with menopause.

• Non-Hormonal: The non-hormonal segment is further bifurcated into antidepressants and others. The rise in the usage of antidepressants to treat vasomotor symptoms drives the growth of this segment over the assessment period. The low-dose selective serotonin reuptake inhibitor (SSRI), a type of medicine usually used to treat depression, is approved by FDA to treat hot flashes in women who do not already have mood or anxiety problems. The other sub-segment includes clonidine and gabapentin, which are used to manage vasomotor symptoms.

By Distribution Channel

• Hospital Pharmacies: The hospital pharmacies segment held a major market share in 2019. The need for a prescription for hormonal treatment is driving the market for hospital pharmacies as the majority of the hospitals have in house pharmacies.

• Online Stores: The rising awareness about the treatment medications and the wide availability of such medications on the e-commerce platforms is driving the growth of this segment, leading it to be the fastest-growing segment during the review period.

• Retail Pharmacies: The growth of the retail pharmacies segment owes to the ease of accessibility of these distribution channels in the developing as well as under-developed economies.

By Region

• Americas: Americas held the largest market share in 2019, owing to the presence of major players, such as Pfizer, Inc., TherapeuticsMD, Inc., and Eli Lilly and Company. These companies have an established clientele in North American as well as Latin American countries, leading to an increase in the market share of the Americas vasomotor symptoms market.

• Europe: The European region holds the second largest share owing to an increase in the clinical trial studies in the European countries. For instance, in April 2020, Mithra Pharmaceuticals, a Belgium-based company announced an update on the Donesta Phase III clinical program called “E4 Comfort”, which aims at enrolling approximately 2200 menopausal women (40-65 years). Thus, such initiatives promise huge growth for the vasomotor symptoms market in European countries.

• Asia-Pacific: The Asia-Pacific region is predicted to be the fastest-growing region in the global vasomotor symptoms market. Vigorous employment of strategic activities by the prominent players aid in the increased market size in this region. For instance, in June 2017, Mithra Pharmaceuticals (Belgium), a company specialized in Women’s Health, signed an Exclusive License and Supply Agreement (LSA) with Fuji Pharma, the leader in Women’s Health in Japan, for the commercialization of Donesta in Japan and ASEAN territories, thus capturing a significant market share in Asian countries.

• Middle East & Africa: This region holds the least share but is likely to rise in the near future due to the inclination of prominent companies to untapped regions. The negative connotation of menopausal symptoms has resulted in a negative attitude towards menopause in premenopausal women. However, with the increasing awareness created by private companies, the scenario is expected to change in the next ten years.

Key Players

• Allergan (Ireland)


• Eli Lily and Company (US)


• Emcure Pharmaceuticals Ltd (India)


• Merck & Co., Inc. (US)


• Mithra Pharmaceuticals (Belgium)


• Novartis AG (Switzerland)


• Novo Nordisk A/S (Denmark)


• Pfizer Inc. (US)


• Teva Pharmaceuticals (Israel)


• TherapeuticsMD, Inc. (US)


• Procter & Gamble (US)


• EndoCeutics, Inc. (Canada)


• Amag Pharmaceuticals (US)